Front Page

Previous Story

Next Story

NIH Record vertical blue bar column separator

New Appointments graphic

Goldman Is New NIAAA Associate Director

Dr. Mark Goldman has joined the leadership of NIAAA as associate director. One of the co-chairs in recent years of NIAAA's task force on college drinking (with Fr. Edward A. Malloy, president of the University of Notre Dame), Goldman has been asked to develop a similar initiative for underage drinkers from 9 to 15 years old and to assist in better integrating behavioral and biomedical research at NIAAA.

Dr. Mark Goldman
He comes to NIAAA from the University of South Florida (USF), where he has been distinguished research professor and director of the Alcohol and Substance Abuse Research Institute since 1985. He will continue to oversee operations in his USF research program while spending most of his time here on an IPA (Intergovernmental Personnel Act agreement).

A psychologist, Goldman's major research interests are alcohol expectancies and cognitive mediators of alcoholism risk and the development of drinking and risk for drinking in children, adolescents and young adults. His work addresses how individuals, especially the young, acquire and process information on the effects, rewards and consequences of alcohol use in making decisions to drink.

One of Goldman's missions as associate director is to develop approaches for the institute to facilitate trans-disciplinary and translational research. Research is uncovering the genetics, neurobiology and neuroanatomy underlying alcohol use, for example, while studies of alcohol expectancies are examining the mechanisms by which information from the environment influences drinking behavior. Goldman, says NIAAA director Dr. T.K. Li, "brings a wealth of research and clinical experience that will be invaluable at this exciting time of discovery in alcohol science."

Goldman received his Ph.D. in 1972 from Rutgers University and served on the faculty of Wayne State University from 1973 until joining USF in 1985. He is a fellow of five divisions of the American Psychological Association (APA), among them the divisions on psychopharmacology and substance abuse and on addictions, and he has been a member and chair of numerous APA professional committees. He is also a member of the American Psychological Society. He has served on a number of scientific advisory and review committees for NIAAA, including the institute's national advisory council. Goldman received a MERIT award from NIAAA in 1992.

Two Join NIAID's Division of AIDS

Two scientists recently joined NIAID's Division of AIDS. Dr. Sandra Lehrman will serve as director of the Therapeutics Research Program, and Dr. Jonathan M. Fishbein will serve as the first director of the Office for Policy in Clinical Research Operations (OPCRO). Lehrman is a physician and virologist with more than 20 years of experience in HIV/AIDS therapeutics research in government, academia and industry. Fishbein is a physician with extensive experience overseeing clinical research for both industrial and academic endeavors, with a focus on clinical product development.

Dr. Sandra Lehrman
Lehrman will manage an array of programs designed to evaluate new treatment strategies and therapeutic agents for HIV and associated complications, and to determine the best use of these drugs and strategies in adults and children worldwide. She will oversee several large clinical trials networks, including the Adult and Pediatric AIDS Clinical Trials Networks and the Community Program for Clinical Research on AIDS; collaborative efforts with other government agencies; and a large portfolio of investigator-initiated grants evaluating new therapeutic agents and combination treatment regimens.

After graduating from Brown University, Lehrman began her professional career as a biologist in NIAID's Laboratory of Infectious Diseases. Subsequently, she returned to Brown and received an M.D. degree. She went on to complete her internship and residency training in pediatrics at Massachusetts General Hospital, and then joined the faculty at Duke University Medical School.

In 1983, Lehrman joined Burroughs Wellcome Co. She led the development of AZT from the laboratory bench to approval by the Food and Drug Administration, and contributed substantially to the development of the use of acyclovir for managing Herpes simplex and Varicella zoster infections.

Lehrman went on to spearhead the startup of several biotechnology companies, including Triangle Pharmaceuticals and CytoTherapeutics, Inc. Before joining the Division of AIDS, she was president and CEO of Genzyme Transgenics Corp.

Dr. Jonathan Fishbein
Fishbein received his M.D. from Johns Hopkins University School of Medicine. He trained in general surgery at Vanderbilt University Medical Center and at Michael Reese Hospital and Medical Center in Chicago before being appointed a medical staff fellow in the Immunology Branch of the National Cancer Institute. He continued his research as a fellow in surgery at the Transplantation Biology Research Center of the Massachusetts General Hospital and Harvard Medical School.

He joins NIAID after a 10-year tenure with PAREXEL International Corp., a leading clinical research organization that conducts and oversees clinical trials for both industrial and academic endeavors. As vice president of the company's North American medical services, he managed the medical, strategic and financial operations of approximately 400 clinical trials, including HIV and other infectious diseases. As the first head of OPCRO, he will address the increasing scientific, ethical and legal complexities surrounding clinical trials, especially in international and resource-poor settings.

CSR Gains Three New SRAs

Dr. Maribeth Champoux
Dr. Maribeth Champoux is a new scientific review administrator at the Center for Scientific Review, coordinating grant application reviews for study sections in two integrated review groups: risk, prevention and health behavior; and integrative, functional and cognitive neuroscience. She recently participated in CSR's Review Internship Program. Champoux previously was a staff scientist in the Laboratory of Comparative Ethology at NICHD. In postdoctoral research at Stanford University, Champoux collected and analyzed behavioral and developmental data from squirrel monkeys. She then moved to NICHD, where she helped to develop its world-class neonatal rhesus monkey nursery and advance genetic and environmental studies of biobehavioral development in these animals.

Dr. Morris Kelsey
Dr. Morris Kelsey has joined the Center for Scientific Review as the scientific review administrator for the new drug discovery and molecular pharmacology study section. He earned his Ph.D. in biochemistry from the University of Pittsburgh and did his postdoctoral research at St. Louis University, studying the metabolites of bile acids. His research continued at Litton Bionetics in Frederick under an NCI contract to assess the role of bile acids and sterols in colon cancer. He later joined NCI's Division of Cancer Etiology to assist efforts in identifying environmental carcinogens. Kelsey is no stranger to peer review. Some years ago, he spent a period of time running the experimental therapeutics I study section in the Division of Research Grants, before it became CSR. Prior to coming to CSR, he was a grants program director in the NCI's Biological Resources Branch in Frederick. In addition he was involved in the manufacture of various biological therapeutics for use by both extramural and intramural scientists in preclinical and clinical studies.

Dr. Michael Steinmetz
Dr. Michael Steinmetz has joined the Center for Scientific Review as scientific review administrator for the central visual processing and the cognitive neuroscience study sections. He comes from Johns Hopkins University, where he has been since receiving his Ph.D. in physiology from Michigan State University in 1982. In postdoctoral studies at JHU, he studied visual perception in the posterior parietal cortex. He continued these studies in JHU's department of neuroscience. Steinmetz's research has shown that the posterior parietal cortex is responsible for redirecting visual attention. Before coming to CSR, he and his colleagues founded a private institute within JHU, the Zanvyl Krieger Mind/Brain Institute, which conducts research on the neural mechanisms of higher brain functions.

Up to Top